Elevance Health Stock News

Elevance Health, Inc.'s Q1 results showed stable Medicare utilization and reaffirmed guidance, in contrast to sector volatility following UnitedHealth Group's rough earnings miss. Medicaid pressures remain, but rate negotiations and targeted acquisitions may support margin recovery by 2026. Carelon Services is growing rapidly, offering diversification away from premium-driven revenue.

Elevance Health, Inc. (NYSE:ELV ) Q1 2025 Earnings Conference Call April 22, 2025 8:30 AM ET Company Participants Nathan Rich - VP, IR Gail Boudreaux - President & CEO Mark Kaye - CFO Felicia Norwood - President, Government Health Benefits Pete Haytaian - President, Carelon Conference Call Participants A.J. Rice - UBS Lance Wilkes - Bernstein Stephen Baxter - Wells Fargo Andrew Mok - Barclays L...

Health insurer Elevance Health said on Tuesday its first-quarter profit came above Street expectations, matching the preliminary estimates it released last week after bellwether UnitedHealth's lowered full-year forecast triggered a selloff in the sector.

INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported first quarter 2025 results. “At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces...

Elevance Health said on Thursday it expects first-quarter profit above estimates, helped by medical cost trends that were in line with its expectations.

For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.

Only a handful of S&P 500 stocks managed to generate gains during the market's historic four-day plunge.

Berkshire Hathaway led Q1 with a 17.5% return, driven by strong operating earnings and potential for significant acquisitions with over $300 billion in cash. Vertex Pharmaceuticals gained 20.4%, fueled by its CF franchise and new therapies, Alyftrek and Journavx, with potential blockbuster status for the latter. Alphabet Inc. was the biggest laggard at -18.3%, impacted by increased capital expe...